Twice-Yearly Injection Raises Hopes and Access Questions in HIV Prevention

A twice-yearly injection being described as the "closest thing to an HIV vaccine" has raised hopes of a major advance in HIV prevention, even as questions persist over who will be able to access it.

Advocates and health experts have pointed to the treatment's potential to significantly reduce new infections if it is made widely available.

A Potential Breakthrough

The injection's twice-yearly dosing schedule marks a departure from daily prevention regimens, an approach that could improve adherence and reach populations that have struggled with existing prevention tools.

Supporters argue that, if deployed effectively, the treatment could meaningfully reduce transmission rates in high-risk communities.

The Access Question

Despite the promise of the treatment, significant questions remain about pricing, distribution and which populations and countries will be prioritized for access.

Public health advocates have cautioned that the impact of the injection will ultimately depend on whether it reaches the communities most affected by HIV, rather than remaining limited to wealthier markets.